Innovent Biologics
Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies.
HQ location
Suzhou Shi, China
Website
Launch date
Employees
Market cap
$15.3b
Enterprise value
$14.6b
Share price
HKD78.40 1801.HK
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | €547m | Post IPO Equity |
| Total Funding | 000k | ||
Legend Capital(exited)
F-Prime(exited)
Frontline BioVentures(exited)
Lilly Asia Ventures(exited)
Hillhouse Capital(exited)
Eight Roads Ventures(exited)
Taikang Life Insurance(exited)
Capital Group(exited)
Rock Springs Capital(exited)
Cormorant Asset Management(exited)
Ally Bridge Group(exited)
Temasek(exited)
SDIC Fund Management(exited)
Ping An Capital(exited)
Ping An Group(exited)
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 11 % | 7 % | 36 % | 52 % | 25 % | 22 % | 28 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (68 %) | (39 %) | (11 %) | 3 % | 7 % | 13 % | 19 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (73 %) | (48 %) | (17 %) | (1 %) | 3 % | 8 % | 14 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 58 % | 63 % | 36 % | 28 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Innovent Biologics
Edit
ACQUISITION by Nuvation Bio Mar 2024